Brain-targeting form of docosahexaenoic acid for experimental stroke treatment: MRI evaluation and anti-oxidant impact

Current Neurovascular Research

Volumn 8, Issue 2, 2011, Pages 95-102

  Chauveau, Fabien ^a,b   Cho, Tae Hee ^a,b   Perez, Magali ^a,c   Guichardant, Michel ^a,c   Riou, Adrien ^a,b   Aguettaz, Pierre ^a,b   Picq, Madeleine ^a,c   Lagarde, Michel ^a,c   Berthezène, Yves ^a,b   Nighoghossian, Norbert ^a,b,d   Wiart, Marlène ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ DE LYON   (France)

^c Univ Lyon   (France)

^d HÔPITAL NEUROLOGIQUE   (France)

Author keywords

Animal model; Docosahexaenoic acid (DHA); Magnetic resonance imaging (MRI); Neuroprotection; Omega 3 fatty acids; Oxidative stress; Stroke

Indexed keywords

DOCOSAHEXAENOIC ACID; ISOPROSTANE DERIVATIVE; LYSOPHOSPHATIDYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BEHAVIORAL RESEARCH; BRAIN; CONTROLLED STUDY; LIPID PEROXIDATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SCORING SYSTEM; STROKE;

EID: 79955734653     PISSN: 15672026     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720211795495349     Document Type: Article

References (32)

1. Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009; 32(7): 365-72.
2. He K, Song Y, Daviglus ML, et al. Fish consumption and incidence of stroke: a meta-analysis of cohort studies. Stroke 2004; 35(7): 1538-42. (Pubitemid 38823619)
3. Cao D, Li M, Xue R, Zheng W, Liu Z, Wang X. Chronic administration of ethyl docosahexaenoate decreases mortality and cerebral edema in ischemic gerbils. Life Sci 2005; 78(1): 74-81. (Pubitemid 41527234)
4. Choi-Kwon S, Park KA, Lee HJ, et al. Temporal changes in cerebral antioxidant enzyme activities after ischemia and reperfusion in a rat focal brain ischemia model: effect of dietary fish oil. Brain Res Dev Brain Res 2004; 152(1): 11-8. (Pubitemid 38993283)
5. Pan HC, Kao TK, Ou YC, et al. Protective effect of docosahexaenoic acid against brain injury in ischemic rats. J Nutr Biochem 2009; 20(9): 715-25.
6. Zhang W, Hu X, Yang W, Gao Y, Chen J. Omega-3 Polyunsaturated Fatty Acid Supplementation Confers Long-Term Neuroprotection Against Neonatal Hypoxic-Ischemic Brain Injury Through Anti-Inflammatory Actions. Stroke 2010; [Epub ahead of print].
7. Belayev L, Marcheselli VL, Khoutorova L, et al. ocosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke 2005; 36(1): 118-23. (Pubitemid 40054186)
8. Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, Lazdunski M. Polyunsaturated fatty acids are potent neuroprotectors. EMBO J 2000; 19(8): 1784-93. (Pubitemid 30204390)
9. Bazan NG. Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. Curr Opin Clin Nutr Metab Care 2007; 10(2): 136-41. (Pubitemid 46220304)
10. Blondeau N, Petrault O, Manta S, et al. Polyunsaturated fatty acids are cerebral vasodilators via the TREK-1 potassium channel. Circ Res 2007; 101(2): 176-84. (Pubitemid 47196585)
11. Lagarde M, Bernoud N, Brossard N, et al. Lysophosphatidylcholine as a preferred carrier form of docosahexaenoic acid to the brain. J Mol Neurosci 2001; 16(2-3): 201-4. (Pubitemid 32664780)
12. Croset M, Brossard N, Polette A, Lagarde M. Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. Biochem J 2000; 345 Pt 1: 61-7. (Pubitemid 30060104)
13. Lagarde M, Guichardant M, Picq M, Michaud S, Doutheau A, inventors; Method for preparing cetyl,docosahexaenoylglycerophosphocholine and use thereof for the delivery of polyunsaturated fatty acids. WO/2008/068413. 2008.
14. Picq M, Chen P, Perez M, et al. DHA metabolism: targeting the brain and lipoxygenation. Mol Neurobiol 2010; 42(1): 48-51.
15. Donnan GA, Baron JC, Ma H, Davis SM. Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol 2009; 8(3):261-9.
16. Donnan GA, Davis SM. Neuroimaging, the ischaemic penumbra, and selection of patients for acute stroke therapy. Lancet Neurol 2002; 1(7): 417-25. (Pubitemid 37159152)
17. Legos JJ, Lenhard SC, Haimbach RE, et al. SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection. Exp Neurol 2008; 212(1): 53-62.
18. Phan TG, Donnan GA, Davis SM, Byrnes G. Proof-of-principle phase II MRI studies in stroke: sample size estimates from dichotomous and continuous data. Stroke 2006; 37(10): 2521-5. (Pubitemid 44454672)
19. Jahn U, Galano JM, Durand T. Beyond prostaglandins-chemistry and biology of cyclic oxygenated metabolites formed by freeradical pathways from polyunsaturated fatty acids. Angew Chem Int Ed Engl 2008; 47(32): 5894-955.
20. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20(1): 84-91. (Pubitemid 19040218)
21. Zaro-Weber O, Moeller-Hartmann W, Heis WD, Sobesky J. MRI Perfusion Maps in Acute Stroke Validated With 15O-Water Positron Emission Tomography. Stroke 2010; 41(3): 443-9.
22. Calamante F, Ganesan V, Kirkham FJ, et al. MR perfusion imaging in Moyamoya Syndrome: potential implications for clinical evaluation of occlusive cerebrovascular disease. Stroke 2001; 32(12): 2810-6. (Pubitemid 33134470)
23. Bardutzky J, Shen Q, Henninger N, Schwab S, Duong TQ, Fisher M. Characterizing tissue fate after transient cerebral ischemia of varying duration using quantitative diffusion and perfusion imaging. Stroke 2007; 38(4): 1336-44. (Pubitemid 351664257)
24. van der Zijden JP, Bouts MJ, Wu O, et al. Manganese-enhanced MRI of brain plasticity in relation to functional recovery after experimental stroke. J Cereb Blood Flow Metab 2008; 28(4): 832-40. (Pubitemid 351432791)
25. Belayev L, Khoutorova L, Atkins KD, Bazan NG. Robust docosahexaenoic acid-mediated neuroprotection in a rat model of transient, focal cerebral ischemia. Stroke 2009; 40(9): 3121-6.
26. Yang DY, Pan HC, Yen YJ, et al. Detrimental effects of posttreatment with fatty acids on brain injury in ischemic rats. Neurotoxicology 2007; 28(6): 1220-9.
27. Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009; 40(6): 2244-50.
28. Thies F, Pillon C, Moliere P, Lagarde M, Lecerf J. Preferential incorporation of sn-2 lysoPC DHA over unesterified DHA in the young rat brain. Am J Physiol 1994; 267(5 Pt 2): R1273-9.
29. Narita K, Kubota M, Nakane M, et al. Therapeutic time window in the penumbra during permanent focal ischemia in rats: changes of free fatty acids and glycerophospholipids. Neurol Res 2000; 22(4): 393-400. (Pubitemid 30409597)
30. Bazan NG. Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. J Lipid Res 2009; 50 Suppl: S400-5.
31. Allen CL, Bayraktutan U. Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int J Stroke 2009; 4(6): 461-70.
32. Kelly PJ, Morrow JD, Ning M, et al. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke 2008; 39(1): 100-4.